Semaglutide shows strong weight loss results for adults over 65

Dansk

A new analysis of clinical trials indicates that semaglutide, the active ingredient in Ozempic and Wegovy, helps older adults with obesity lose substantial weight and improve heart health markers. The findings come from data on participants aged 65 and above who received the once-weekly medication alongside lifestyle changes.

Researchers led by Prof Luca Busetto at the University of Padova examined results from the STEP 1, 3, 4, 5, 8 and 9 trials. The analysis focused on 358 adults aged 65 or older with obesity but without diabetes. Of these, 248 took semaglutide 2.4 mg while 110 received a placebo over 68 weeks.

Relaterede artikler

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.
Billede genereret af AI

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Rapporteret af AI Billede genereret af AI Faktatjekket

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Study links Ozempic to lower depression and anxiety risks

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

Rapporteret af AI

A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.

Sundhed

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Sundhed

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Sundhed

Gut reset procedure limits weight regain after stopping Ozempic

Trojan horse obesity drug boosts weight loss in mice

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Rapporteret af AI

Young Indians are turning to diabetes drugs Ozempic and Mounjaro for rapid weight loss before weddings and job interviews, as experts warn of cosmetic misuse, grey market dangers, and rising lookism. These GLP-1 drugs are meant for obesity and diabetes, not vanity purposes, doctors emphasize.

Studie anbefaler behandling til alle børn med svær overvægt

Et nyt studie fra Karolinska Institutet viser, at børn med moderat overvægt har en højere risiko for type 2-diabetes, forhøjet blodtryk og forstyrrelser i fedtstofferne i voksenlivet, selv uden tydelige risikomarkører. Forskerne opfordrer til behandling af alle børn i denne gruppe.

Testosterone gel plus exercise may limit visceral fat gain in older women recovering from hip fractures

Rapporteret af AI Faktatjekket

A University of Connecticut-led clinical trial found that older women recovering from a recent hip fracture who used a topical testosterone gel alongside a structured exercise program did not experience the typical rise in visceral abdominal fat seen during recovery. Researchers followed participants for six months and assessed body composition with imaging scans.

torsdag d. 9. april 2026, 23.54

Vanderbilt study finds muscle loss with weight loss drugs and surgery

mandag d. 30. marts 2026, 15.21

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

torsdag d. 19. marts 2026, 14.37

Study finds prediabetes remission possible without weight loss

onsdag d. 11. marts 2026, 20.38

GLP-1 weight loss drugs boost premium chocolate sales

søndag d. 1. marts 2026, 21.06

Animal study raises new questions about gut effects of SNAC, an ingredient used in oral semaglutide tablets

torsdag d. 19. februar 2026, 04.17

Ny undersøgelse giver håb for vægttabsmedicin mod alkoholisme

onsdag d. 18. februar 2026, 15.06

Cochrane review finds intermittent fasting no better for weight loss

tirsdag d. 17. februar 2026, 21.33

AI digital twins help manage diabetes and obesity

fredag d. 13. februar 2026, 14.01

India today investigation reveals lax drug norms for weight loss injections

onsdag d. 11. februar 2026, 10.54

Cochrane reviews assess GLP-1 drugs for obesity treatment

 

 

 

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis